Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-15 · accession 0002001011-24-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-17 | 2024-05-15+ | LGND | Espinoza Octavio | CFO | S - Sale+OE | $86.26 | -13.3K | 23.5K | -36% | -$1.15M |
| DM | 2024-05-17 | 2024-05-17 | LGND | Espinoza Octavio | CFO | M - OptEx | $55.71 | +6,917 | 23.4K | +42% | +$385.3K |
| DM | 2024-05-17 | 2024-05-17 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -6,917 | 18.5K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-15 | S | D | 5,873 | $86.01 | 23,882 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-05-16 | S | D | 2,264 | $86.00 | 21,618 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-05-17 | M | A | 206 | $57.22 | 21,824 | D | — | — | |
| 4 | Common | Common Stock | 2024-05-17 | S | D | 134 | $86.65 | 23,379 | D | — | — | |
| 5 | Common | Common Stock | 2024-05-17 | M | A | 145 | $68.74 | 23,513 | D | — | — | |
| 6 | Common | Common Stock | 2024-05-17 | M | A | 5,022 | $52.84 | 28,535 | D | — | — | |
| 7 | Common | Common Stock | 2024-05-17 | S | D | 5,022 | $86.67 | 23,513 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2024-05-17 | M | A | 1,544 | $63.62 | 23,368 | D | — | — | |
| 9 | Derivative | Employee Stock Option (right to buy) | 2024-05-17 | M | D | 206 | $0.00 | 7,516 | D | $57.22 · — to 2030-10-01 | 206 Common Stock | (F4) As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-05-17 | M | D | 5,022 | $0.00 | 16,179 | D | $52.84 · — to 2032-05-05 | 5,022 Common Stock | (F7) The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. |
| 11 | Derivative | Incentive Stock Option (right to buy) | 2024-05-17 | M | D | 145 | $0.00 | 0 | D | $68.74 · — to 2029-02-11 | 145 Common Stock | (F6) The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023. |
| 12 | Derivative | Employee Stock Option (right to buy) | 2024-05-17 | M | D | 1,544 | $0.00 | 18,456 | D | $63.62 · — to 2032-12-13 | 1,544 Common Stock | (F5) Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. |